This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): WT2725
Description: WT2725 is a therapeutic cancer vaccine candidate using a peptide derived from Wilms’ tumor gene 1 (WT1) protein. The vaccine is expected to treat patients with various types of hematologic and solid cancers that overexpress WT1 by the induction of WT1-specific cytotoxic T-lymphocytes to attack cancer cells expressing WT1 protein.
Dainippon Sumitomo and Chugai
WT2725 was being jointly developed by Dainippon Sumitomo and Chugai.
In April 2013, Dainippon Sumitomo (DSP) and Chugai have agreed to terminate the joint development agreement for WT4869 and WT2725. As a result, future development plans will change. DSP and Chugai have jointly conducted the development of WT4869 and WT2725. However, in order to provide these treatment options to patients as early as possible, the companies concluded that it would be preferable to concentrate development and marketing activities to DSP, and agreed to terminate the joint development agreement. The ongoing Phase I clinical study of WT4869 in Japan will continue to be jointly developed until completion of the studies. Subsequent clinical development for WT4869, and the ongoing development for WT2725 in the U.S. will be solely conducted by DSP. Chugai will receive royalties from DSP after launch in return for its contribution in development.
Partners: Chugai Pharmaceutical Co., Ltd. Roche Holding AG
Additional information available to subscribers only: